Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dacarbazine + Unesbulin |
Synonyms | |
Therapy Description |
PTC596 is a small molecule inhibitor of BMI-1, which may result in mitochondrial induced apoptosis in cancer cells (PMID: 28211885). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dacarbazine | Deticene | Biocarbazine R | Chemotherapy - Alkylating 18 | Deticene (dacarbazine) alkylates and cross-links DNA, which disrupts the cell-cycle. Dacarbazine is FDA approved for melanoma (FDA.gov). |
Unesbulin | PTC596|PTC-596|PTC 596 | Unesbulin (PTC596) inhibits BMI-1, which may result in mitochondrial apoptosis in cancer cells (PMID: 28211885, PMID: 32232850, PMID: 38684039). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03761095 | Phase I | Dacarbazine + Unesbulin | A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) | Completed | USA | 0 |